Diversify Wealth Management LLC Has $1.46 Million Position in argenex SE $ARGX

Diversify Wealth Management LLC increased its holdings in shares of argenex SE (NASDAQ:ARGX) by 590.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,884 shares of the company’s stock after purchasing an additional 1,611 shares during the period. Diversify Wealth Management LLC’s holdings in argenex were worth $1,462,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Abound Wealth Management increased its stake in argenex by 3,200.0% during the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after purchasing an additional 32 shares in the last quarter. Sound Income Strategies LLC acquired a new stake in argenex during the 4th quarter worth approximately $28,000. Whipplewood Advisors LLC bought a new position in argenex in the first quarter valued at approximately $28,000. Aventura Private Wealth LLC bought a new position in argenex in the fourth quarter valued at approximately $38,000. Finally, Sunbelt Securities Inc. acquired a new position in shares of argenex in the third quarter valued at approximately $36,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Stock Down 1.9%

ARGX stock opened at $859.43 on Wednesday. The company has a market cap of $53.45 billion, a price-to-earnings ratio of 38.26, a P/E/G ratio of 1.08 and a beta of 0.45. argenex SE has a twelve month low of $554.59 and a twelve month high of $953.58. The business has a 50 day moving average price of $856.89 and a two-hundred day moving average price of $813.08.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The company had revenue of $1.31 billion for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%. On average, equities research analysts anticipate that argenex SE will post 26.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a research report on Thursday, June 11th. Bank of America boosted their price objective on shares of argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $940.00 target price on shares of argenex in a research note on Thursday, June 25th. Guggenheim increased their target price on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Weiss Ratings upgraded argenex from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, argenex presently has an average rating of “Moderate Buy” and a consensus target price of $1,037.61.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.